Home › Niet-kleincellige longkanker › Virginia › Alexandria
Niet-kleincellige longkanker klinische studies in Alexandria, VA
11 studies voor Niet-kleincellige longkanker zoeken deelnemers op locaties in en rond Alexandria (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruterenFase 3
- Kaiser Permanente-Caton Hill Medical Center, Woodbridge · 15 mijl verwijderd
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RekruterenFase 3
- Maryland Oncology Hematology, PA, Brandywine · 13 mijl verwijderd
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekruterenFase 3
- Maryland Oncology Hematology, P.A., Brandywine · 13 mijl verwijderd
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RekruterenFase 3
- Research Site, Fort Belvoir · 8 mijl verwijderd
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RekruterenFase 2/3
- Local Institution - 007-814-A, Alexandria
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RekruterenFase 3
- Research Site, Brandywine · 13 mijl verwijderd
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
RekruterenFase 3
- Research Site, Fort Belvoir · 8 mijl verwijderd
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RekruterenFase 3
- Inova Alexandria Hospital, Alexandria
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruterenFase 2
- Kaiser Permanente-Caton Hill Medical Center, Woodbridge · 15 mijl verwijderd
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruterenFase 2/3
- Kaiser Permanente-Caton Hill Medical Center, Woodbridge · 15 mijl verwijderd
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruterenFase 2
- Kaiser Permanente-Caton Hill Medical Center, Woodbridge · 15 mijl verwijderd
Niet-kleincellige longkanker studies in andere steden
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Andere studies in Alexandria
- Longkanker7 studies
- Borstkanker6 studies
- Type 2-diabetes5 studies
- Atherosclerose5 studies
- Cardiovasculaire ziekte5 studies
- Dikkedarmkanker4 studies
- Hoge bloeddruk4 studies
- Obesitas4 studies
- Maagkanker3 studies
- Colorectale kanker3 studies
- Overgewicht3 studies
- Beroerte3 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.